Voyageur Pharmaceuticals Partners with Red Cloud Securities for Enhanced Market Liquidity on TSXV

Details of the Market-Making Agreement and Structure

Voyageur Pharmaceuticals formalized a market-making agreement with Toronto-based Red Cloud Securities, a member of the Canadian Investment Regulatory Organization (CIRO), dated July 14, 2026. Subject to TSX Venture Exchange approval, Red Cloud will provide market stabilization and liquidity services, reflecting Voyageur's strategic initiative to improve trading conditions on the TSXV.

The compensation framework is straightforward: Voyageur will pay Red Cloud a monthly retainer of $5,000 throughout the engagement. The contract excludes any performance-based compensation and does not grant shares or options to Red Cloud. This arrangement complies with TSXV policies and applicable securities regulations governing market-making activities.

Terms of Engagement and Termination Clauses

The engagement operates on an ongoing basis, with either party entitled to terminate the agreement by providing 60 days’ prior written notice, facilitating an orderly wind-down if necessary. This termination provision aligns with standard market-making agreements, providing flexibility to both parties.

At the agreement's inception, Red Cloud holds no direct or indirect interest in Voyageur securities. However, the announcement notes that Red Cloud and its clients may acquire interests in the company's securities during the engagement. The relationship remains at arm's length, with Red Cloud's mandate focused on trading Voyageur shares on the TSXV to maintain reasonable market conditions and enhance liquidity, rather than promoting specific transactions.

Red Cloud Securities’ Market-Making Role and Responsibilities

Red Cloud Securities is a full-service investment dealer with expertise in the junior resource sector, offering investment banking, research, institutional and retail trading, sales, and advisory services. By engaging Red Cloud, Voyageur benefits from an experienced dealer capable of supporting junior public companies on Canadian exchanges.

As Voyageur’s market maker, Red Cloud’s primary role is to facilitate orderly trading by maintaining a consistent market presence on the TSXV. Market-making services aim to tighten bid-ask spreads, ensure trading continuity, and enhance overall liquidity—crucial factors for smaller-cap companies seeking to attract and retain investors.

Regulatory Approval and Exchange Oversight

The partnership remains subject to all necessary regulatory approvals, most notably from the TSX Venture Exchange. The TSXV enforces policies and guidelines to uphold fair dealing and market integrity in market-making activities. Both parties are working within this compliance framework, requiring TSXV acceptance before the arrangement becomes fully operational.

Red Cloud’s membership in CIRO ensures adherence to a comprehensive regulatory regime established by Canada’s investment industry regulator. This oversight applies to all market-making functions performed on behalf of Voyageur, assuring investors that the engagement complies with industry standards and legal requirements.

Voyageur’s Focus on Pharmaceutical Contrast Media

Voyageur Pharmaceuticals is a Canadian public company dedicated to developing pharmaceutical-grade barium and iodine contrast media used in medical imaging. The company’s strategy emphasizes producing high-performance, cost-effective imaging contrast agents for the medical and diagnostic imaging industries. Voyageur has developed five barium contrast products licensed by Health Canada, positioning it as an active participant in this niche pharmaceutical market.

The company pursues vertical integration across barium and iodine contrast media markets, controlling raw material sourcing, manufacturing, and distribution—summarized by its motto "From Earth to Bottle." This approach enables Voyageur to optimize product quality and cost efficiency by managing the entire supply chain from mineral extraction to final production.

Frances Creek Barium Sulfate Project and Raw Material Strategy

Voyageur holds a 100% interest in the Frances Creek barium sulfate (barite) project, a key asset in its vertical integration strategy. This project offers a rare, high-grade mineral resource suitable for pharmaceutical applications. The company notes that the global pharmaceutical barium sulfate market is predominantly synthetic, which management believes yields inferior imaging quality compared to naturally sourced, high-grade mineral alternatives.

Voyageur’s strategic focus on the Frances Creek resource reflects its belief that natural, pharmaceutical-grade barium will eventually supplant synthetic alternatives. Controlling this critical input allows the company to offer differentiated products with superior imaging quality at lower costs compared to competitors reliant on synthetic sources. This resource advantage is central to Voyageur’s long-term business and market positioning.

Manufacturing and Market Development Approach

In the near term, Voyageur plans to collaborate with established third-party GMP (Good Manufacturing Practice) pharmaceutical manufacturers in Canada. This partnership enables product validation and production to international regulatory standards without the capital-intensive investment in in-house manufacturing facilities during early commercialization stages. Such arrangements are common in pharmaceutical development, providing access to validated manufacturing capacity efficiently.

Voyageur’s long-term vision includes transitioning to direct manufacturing of radiology drugs as its market presence grows. By initially leveraging third-party manufacturing, the company aims to build market share and customer relationships before investing in high-margin domestic manufacturing capacity. This phased vertical integration strategy balances capital constraints with revenue growth objectives.

Pharmaceutical Contrast Media Market Context

The medical imaging contrast media market is a specialized segment within global pharmaceuticals, with barium and iodine agents playing vital roles in radiological diagnostics. These contrast agents enable visualization of internal organs and structures during imaging procedures, making them essential in healthcare worldwide. Demand correlates with healthcare spending, diagnostic imaging utilization, and regulatory standards for product quality and safety.

Voyageur’s entry into this market through high-quality, cost-effective contrast agents positions it within a sector characterized by established demand and clear regulatory pathways. The company’s focus on pharmaceutical-grade products and Health Canada licensing underscores its commitment to regulatory compliance and product quality. Engaging a market maker likely reflects Voyageur’s intent to strengthen its capital markets profile as it advances product commercialization.

Forward-Looking Statements and Market Implications

The announcement includes forward-looking statements about Voyageur’s goals to become a leading player in the barium and iodine contrast media markets, secure TSXV approval of the market-making agreement, and transition to high-margin domestic manufacturing. These statements represent management’s current expectations but are subject to risks and uncertainties inherent in pharmaceutical development and manufacturing.

The market-making engagement may indicate management’s confidence in the company’s growth and commercialization prospects. Nonetheless, investors should recognize that share liquidity and market conditions depend on multiple factors, including market sentiment, company developments, and broader economic and sector-specific influences affecting junior pharmaceutical companies.